ERBB2 and neoplasm: To assess whether the vaccine-induced HER2/neu-specific T-cell immunity can mediate protective anti-tumor immunity, we immunized FVB/N mice with DEC-HER2 or Ctrl Ig-HER2 in combination with poly IC.